Trying to Measure the Quality of Health Information on the Internet: Is It Time to Move On? A. Deshpande, A.R. Jadad ........................................ 1
Overlap Between Systemic Lupus Erythematosus and Rheumatoid Arthritis: Is It Real or Just an Illusion? L.M. Amezcua-Guerra .............................................................. 4
More May Not Be Better — But Is Less Enough? H.I. Brunner ................................................................................................. 7
How to Assess Patients with Rheumatoid Arthritis and Concomitant Fibromyalgia? H. Mäkinen, P. Hannonen .................................................. 9
Association Between IL-1 Polymorphisms and RA Susceptibility: A Metaanalysis Y.H. Lee, J.D. Ji, G.G. Song ........................................ 12
Cost-Effectiveness of Sequential Therapy with TNF Antagonists in Early RA A. Davies, M.A. Cifaldi, O.G. Segurado, M.H. Weisman .......... 16
Proposed Metrics for the Determination of RA Outcome and Treatment Success and Failure F. Wolfe, K. Michaud .......................... 27
The Role of Traditional Cardiovascular Risk Factors Among Patients with RA S.R.E. Brady, B. de Courten, C.M. Reid, F.M. Cicuttini, M.P.J. de Courten, D. Liew ........................................... 34
Patient-Oriented Methotrexate Information Sites on the Internet: A Review of Completeness, Accuracy, Format, Reliability, Credibility, and Readability A.E. Thompson, S.L. Graydon ........................................ 41
SLE Features in RA and Their Effect on Overall Mortality M. Icen, P.J. Nicola, H. Maradit-Kremers, et al ........................................ 50
RA and Fibromyalgia: A Frequent Unrelated Association Complicating Disease Management F. Coury, A. Rossat, A. Tebib, et al.................................................. 58
Thrombosis in SLE and Other Autoimmune Diseases of Recent Onset J. Romero-Diaz, I. García-Sosa, J. Sánchez-Guerrero .......................... 68
Fibromyalgia, SLE, and Evaluation of SLE Activity F. Wolfe, M. Petri, G.S. Alarcón, et al .................................................. 82
Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with SLE A.D. Askanase, D.J. Wallace, M.H. Weisman, et al ........................................ 89
Demographic and Clinical Factors Associated with Physician Service Use in SSC S. Bernatsky, P. Panopoulos, M. Hudson, et al, and the Canadian Scleroderma Research Group ........................................ 96
Cardiac MRI with Pharmacological Stress Perfusion and Delayed Enhancement in Asymptomatic Patients with SSC H. Kobayashi, I. Yokoe, M. Hirano, et al ........................................ 106
Determination of the Subset of Sjögren’s Syndrome with Articular Manifestations by Anti-CCP Antibodies N. Inamoto, A. Kawakami, M. Tamai, et al ........................................ 113
Limited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis C.L. Koening, J. Hernández-Rodríguez, E.S. Molloy, T.M. Clark, G.S. Hoffman ........................................ 116
The HLA-B27 Transgenic Rat, a Model of SpA, Has Decreased BMD and Increased RANKL to Osteoprotegerin mRNA Ratio M. Rauner, D. Stuppan, M. Haas, et al ........................................ 120
Uveitis Subtypes in a German Interdisciplinary Uveitis Center — Analysis of 1916 Patients E. Jakob, M.S. Reuland, F. Mackensen, et al ........................................ 127
Telomerase Transduced OA Fibroblast-like Synoviocytes Display a Distinct Gene Expression Profile Y. Sun, D.R. Mauerhan, G.S. Firestein, B.J. Loeffler, E.N. Hanley, H.E. Gruber ........................................ 141
The Mid-Range of the Adjusted Level of Ferritin Can Predict the Chronic Course in Patients with Adult Onset Still’s Disease S-W. Lee, Y-B. Park, J-S. Song, S-K. Lee ........................................ 156

Contents continued opposite inside back cover . .